Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
Public ClinicalTrials.gov record NCT01289990. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Double-blind, Extension, Placebo-controlled Parallel Group Safety and Efficacy Trial of BI 10773 (10 and 25mg Once Daily) and Sitagliptin (100mg Once Daily) Given for Minimum 76 Weeks (Incl. 24 Weeks of Preceding Trial) as Monotherapy or With Different Back-ground Therapies in Patients With Type 2 Diabetes Mellitus Previously Completing Trial 1245.19, 1245.20 or 1245.23
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
Study identification
- NCT ID
- NCT01289990
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 2,705 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2011 (Type not available)
- Primary completion
- May 2013 (Actual)
- Completion
- May 2013 (Actual)
- Last update posted
- Jul 15, 2014
2011 – 2013
United States locations
- U.S. sites
- 40
- U.S. states
- 18
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1245.31.10145 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 1245.31.10162 Boehringer Ingelheim Investigational Site | Glendale | Arizona | — | — |
| 1245.31.10124 Boehringer Ingelheim Investigational Site | Mesa | Arizona | — | — |
| 1245.31.10108 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 1245.31.10046 Boehringer Ingelheim Investigational Site | Tempe | Arizona | — | — |
| 1245.31.10154 Boehringer Ingelheim Investigational Site | Chino | California | — | — |
| 1245.31.10149 Boehringer Ingelheim Investigational Site | Rancho Cucamonga | California | — | — |
| 1245.31.10131 Boehringer Ingelheim Investigational Site | West Hills | California | — | — |
| 1245.31.10038 Boehringer Ingelheim Investigational Site | Northglenn | Colorado | — | — |
| 1245.31.10127 Boehringer Ingelheim Investigational Site | Waterbury | Connecticut | — | — |
| 1245.31.10137 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1245.31.10133 Boehringer Ingelheim Investigational Site | Jupiter | Florida | — | — |
| 1245.31.10006 Boehringer Ingelheim Investigational Site | Miami | Florida | — | — |
| 1245.31.10085 Boehringer Ingelheim Investigational Site | Plantation | Florida | — | — |
| 1245.31.10080 Boehringer Ingelheim Investigational Site | Decatur | Georgia | — | — |
| 1245.31.10077 Boehringer Ingelheim Investigational Site | Perry | Georgia | — | — |
| 1245.31.10001 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 1245.31.10159 Boehringer Ingelheim Investigational Site | Des Moines | Iowa | — | — |
| 1245.31.10014 Boehringer Ingelheim Investigational Site | Dubuque | Iowa | — | — |
| 1245.31.10117 Boehringer Ingelheim Investigational Site | Arkansas City | Kansas | — | — |
| 1245.31.10157 Boehringer Ingelheim Investigational Site | Newton | Kansas | — | — |
| 1245.31.10146 Boehringer Ingelheim Investigational Site | Louisville | Kentucky | — | — |
| 1245.31.10003 Boehringer Ingelheim Investigational Site | Dearborn | Michigan | — | — |
| 1245.31.10059 Boehringer Ingelheim Investigational Site | New Hyde Park | New York | — | — |
| 1245.31.10034 Boehringer Ingelheim Investigational Site | Rochester | New York | — | — |
| 1245.31.10123 Boehringer Ingelheim Investigational Site | Smithtown | New York | — | — |
| 1245.31.10071 Boehringer Ingelheim Investigational Site | Asheboro | North Carolina | — | — |
| 1245.31.10086 Boehringer Ingelheim Investigational Site | Salisbury | North Carolina | — | — |
| 1245.31.10129 Boehringer Ingelheim Investigational Site | Carlisle | Ohio | — | — |
| 1245.31.10045 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1245.31.10119 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 1245.31.10130 Boehringer Ingelheim Investigational Site | Gallipolis | Ohio | — | — |
| 1245.31.10158 Boehringer Ingelheim Investigational Site | Mt. Pleasant | South Carolina | — | — |
| 1245.31.10015 Boehringer Ingelheim Investigational Site | Simpsonville | South Carolina | — | — |
| 1245.31.10033 Boehringer Ingelheim Investigational Site | Chattanooga | Tennessee | — | — |
| 1245.31.10112 Boehringer Ingelheim Investigational Site | Memphis | Tennessee | — | — |
| 1245.31.10156 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1245.31.10151 Boehringer Ingelheim Investigational Site | Hurst | Texas | — | — |
| 1245.31.10143 Boehringer Ingelheim Investigational Site | Killeen | Texas | — | — |
| 1245.31.10155 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 203 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01289990, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2014 · Synced Oct 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01289990 live on ClinicalTrials.gov.